Use of the 13-valent pneumococcal conjugate vaccine in infants and young children

Expert Opinion on Biological Therapy

Volumn 12, Issue 5, 2012, Pages 641-648

  Principi, Nicola ^a   Esposito, Susanna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

13 valent pneumococcal conjugate vaccine; conjugate pneumococcal vaccine; invasive pneumococcal disease; pediatrics; pneumococcal infections; prevention

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INCIDENCE; PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE; VACCINATION;

CHILD, PRESCHOOL; HUMANS; INFANT; PNEUMOCOCCAL VACCINES;

STREPTOCOCCUS PNEUMONIAE;

EID: 84859624900     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.670217     Document Type: Review

References (66)

1. Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Expert Rev Vaccines 2008;7:1367-94
2. Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines 2009;8:1351-64
3. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-21
4. Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000;30:122-40
5. Buckingham SC, King MD, Miller ML. Incidence and etiologies of complicated parapneumonic effusions in children, 1996 to 2001. Pediatr Infect Dis 2003;22:499-504 (Pubitemid 36782188)
6. Eltringham G, Kearns A, Freeman R, et al. Culture-negative childhood empyema is usually due to penicillin-sensitive Streptococcus pneumoniae capsular serotype 1. J Clin Microbiol 2003;41:521-2 (Pubitemid 36098641)
7. Hardie W, Bokulic R, Garcia VF, et al. Pneumococcal pleural empyemas in children. Clin Infect Dis 1996;22:1057-63 (Pubitemid 26260612)
8. Camou T, Palacio R, Di Fabio JL, et al. Invasive pneumococcal diseases in Uruguayan children: comparison between serotype distribution and conjugate vaccine formulations. Vaccine 2003;21:2093-6
9. Bender JM, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis 2008;46:1346-52 (Pubitemid 351589931)
10. Munoz-Almagro C, Jordan I, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008;46:174-82 (Pubitemid 351269154)
11. Choi YH, Jit M, Gay N, et al. 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement? PLoS One 2011;6:e26190
12. Dias R, Canica M. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol Med Microbiol 2007;51:35-42 (Pubitemid 47387484)
13. World Health Organization. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec 2010;85:434-6
14. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010;28:4249-59 This review summarizes the published literature to analyze the factors contributing to the emergence of serotype 19A, the diseases associated with it, and the importance of including it in novel PCV7.
15. Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccine: PHiD-CV. Expert Rev Ant Infect Ther 2009;7:1063-74
16. Paradiso PR. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis 2011;52:1241-7 A comprehensive and well-written review of the immunogenicity, safety, tolerability of PCV13, with a recommended schedule based on vaccination history.
17. Garcia S, Levine OS, Cherian T, et al. Pneumococcal disease and vaccination in the Americas: an agenda for accelerated vaccine introduction. Rev Panam Salud Publica 2006;19:340-8 (Pubitemid 44249856)
18. Brooks WA, Brieman RF, Goswani D, et al. Invasive pneumococcal disease burden and implications for vaccine policy in urban Bangladesh. Am J Trop Med Hyg 2007;77:795-801 (Pubitemid 351837816)
19. Levine S, Dejsirilert S, Sangsuk L, et al. Serotypes and antimicrobial resistance of Streptococcus pneumoniae in Thailand 2002-2004. Pediatr Infect Dis J 2006;25:176-8 (Pubitemid 43208577)
20. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 2007;25:2406-12 (Pubitemid 46366120)
21. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196:1346-54 (Pubitemid 351412007)
22. Ampofo K, Pavia AT, Stockmann C, et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the PCV7 era. Pediatr Infect Dis J 2011; [Epub ahead of print] A study showing significant changes in IPD after the introduction of PCV7. One-third of the IPDs occurred in children aged > 5 years, who were outside the age range for which PCV is recommended.
23. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11:760-8 An interesting study demonstrating that, despite much serotype replacement, a substantial reduction in IPD in young children can be achieved using PCV7 vaccinations, and some indirect benefits in older age groups.
24. van Gils EJM, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomizedcontrolled trial. JAMA 2009;302:159-67
25. Lipsitch M, O'Neill K, Cordy D, et al. Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. J Infect Dis 2007;196:1221-7 (Pubitemid 47580277)
26. Cheung Y-B, Zaman SMA, Nsekpong ED, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J 2009;28:990-5
27. Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on serotypes, antibiotic resistance, and risk factors for carriage in young children. Pediatrics 2009;124:e1-11
28. Vestrheim DF, Hoiby EA, Aaberge IS, et al. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 2010;17:325-34
29. Cohen R, Levy C, Bonnet E, et al. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine 2010;28:6114-21
30. Dunais B, Bruno P, Carsenti-Dellamonica H, et al. Trends in nasopharyngeal carriage of Streptococcus pneumoniae among children attending daycare centers in southeastern France from 1999 to 2006. Pediatr Infect Dis J 2008;27:1033-5
31. Ho PL, Chiu SS, Chan MY, et al. Changes in nasopharyngeal carriage and serotype distribution of antibiotic-resistant Streptococcus pneumoniae before and after the introduction of 7-valent pneumococcal conjugate vaccine in Hong Kong. Diagn Microbiol Infect Dis 2011;71:327-34 A well-conducted study of the impact of PCV-7 on the prevalence of antibiotic resistance.
32. Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005;192:1988-95 (Pubitemid 41681898)
33. Lee H, Nahm MH, Burton R, et al. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 2009;16:376-81
34. World Health Organization. 2007. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007;82:93-104
35. World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. World Health Organ Tech Rep Ser 2005;927:64-98
36. Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010;126:e493-505
37. Romero-Steiner S, Frasch CE, Carlone G, et al. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006;13:165-9 (Pubitemid 43383782)
38. Cooper D, Yu X, Sidhu M, et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011;29:7207-11
39. Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010;28:4192-203
40. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010;17:1017-26 The first study of PCV13 administered simultaneously with hexavalent vaccine using the Italian schedule.
41. Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis 2010;29:e80-90
42. Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J 2010;29:756-62
43. Gadzinowski J, Albrecht P, Hasiec B, et al. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29:2947-55
44. Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines 2010;9:229-36
45. Centers for Disease Control and Prevention. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged < 59 months - Selected U.S. Regions, 2010-2011. MMWR 2011;60:1477-81
46. Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics 2010;125:26-33 An interesting study of the epidemiology of pediatric empyema in the USA in relation to PCV7 use.
47. Grijalva CG, Nuorti JP, Zhu Y, et al. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis 2010;50:805-13
48. Centers for Disease Control and Prevention. Licensure of a 13-valent conjugate vaccine (PCV13) and recommendation for use among children - Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:258-61 A complete review of PCV13 and its recommendations for use in pediatrics.
49. Ministero della Salute. Indicazioni in merito alla somministrazione del vaccino Antipneumococcico Prevenar 13 in eta pediatrica. Italian Ministry of Health circular of 27 May 2010
50. Frenck R Jr, Thompson A, Yeh SH, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2011;30:1086-91 A study demonstrating that PCV13 works well in children previously immunized with PCV7.
51. Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010;28:7634-43
52. Messonnier ML, Zhou F, Nuorti P. Cost-effectiveness of using 13-valent pneumococcal conjugate vaccine in infants and young children to prevent pneumococcal disease in the United States 2009. Available from: http://www.cdc.gov/vaccines/recs/ACIP/downloads/mtg-slides-oct09/11-1-PCV13.pdf [Accessed 16 September 2010]
53. Boccalini S, Azzari C, Resti M, et al. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy. Vaccine 2011;29:9521-8 The results of this study justify (also from the economic point of view) the recommendation of the Italian Ministry of Health to vaccinate children aged up to 24 months in a catch-up program, and the administration of PCV13 to children aged up to 36 months as already done in some Italian regions. Furthermore, a catch-up program that provides for the immunization of children aged < 60 months is also justified economically and clinically.
54. Link-Gelles R, Farley M, Thomas A, et al. Early impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children < 2 years old, US, 2010 [Abstract G1-538]. Proceedings of the 51st International Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2011; Chicago
55. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29:9127-31
56. Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010;28:7634-43
57. Bin-Chia Wu D, Chang CJ, Huang YC, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach. Value Health 2012;15(1 Suppl):S15-19
58. Robberstad B, Frostad CR, Akselsen PE, et al. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine 2011;29:8564-74
59. Souza CPR, Morales JC, Berezin E, et al. Cost effectiveness analysis of 13-valent pneumococcal conjugate vaccine in prevention of pneumococcal disease within the SUS scenario. Economic evaluation of pneumococcal vaccine. J Bras Econ Saude 2009;1:103-11
60. Uruena A, Pippo T, Betelu MS, et al. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine 2011;29:4963-72
61. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:1-18 A comprehensive review on when to recommend PCV13 or 23-valent pneumococcal polysaccharide vaccine in patients with chronic underlying disease.
62. Munoz-Almagro C, Ciruela P, Esteva C, et al. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J Infect 2011;63:151-62
63. Resti M, Moriondo M, Cortimiglia M, et al. Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. Clin Infect Dis 2010;51:1042-9
64. Principi N, Esposito S. Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza. Hum Vaccin 2011;7:905-12 A comprehensive review of pneumococcal vaccines, with a large section concerning pneumococcal vaccines.
65. Denoel P, Philipp MT, Doyle L, et al. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 2011;29(33):5495-501
66. Goulart C, Darrieux M, Rodriguez D, et al. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine 2011;29:1634-42